

**Listing of Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-9. (canceled).

Claim 10. (currently amended) A mutant *ras* peptide comprising:  
an amino acid sequence of at least 8 ~~to no more than 13~~ amino acids, ~~wherein said amino acid~~ **from the** sequence ~~comprises~~ **consisting of** Xaa<sub>1</sub> Leu Xaa<sub>2</sub> Val Val Gly Ala Xaa<sub>3</sub> Gly Val **Gly Lys Ser** (SEQ ID NO:14 ~~14~~ **15**);  
wherein Xaa<sub>1</sub> is the amino acid lysine or tyrosine;  
wherein Xaa<sub>2</sub> is an amino acid;  
wherein Xaa<sub>3</sub> is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, ~~or~~ **and** serine;  
wherein when Xaa<sub>2</sub> is valine, Xaa<sub>1</sub> is tyrosine  
and said peptide elicits a peptide-specific human CD8<sup>+</sup> cytotoxic T lymphocyte immune response.

Claim 11. (currently amended): The mutant *ras* peptide of claim 10 **or 72**, wherein the peptide comprises an amino acid sequence of 13 amino acids.

Claim 12. (currently amended): The mutant *ras* peptide of claim 10 **or 72**, wherein the peptide comprises an amino acid sequence of 10 amino acids.

Claim 13. (currently amended): The mutant *ras* peptide of claim 10 **or 72**, wherein Xaa<sub>1</sub> is tyrosine.

Claim 14. (currently amended): The mutant *ras* peptide of claim 10 **or 72**, wherein Xaa<sub>2</sub> is selected from the group consisting of valine, tryptophan, leucine, tyrosine, and phenylalanine.

Claim 15. (currently amended): The mutant *ras* peptide of claim 10 or 72 wherein Xaa<sub>1</sub> is tyrosine, and Xaa<sub>3</sub> is aspartic acid.

Claims 16-24. (canceled).

Claim 25. (currently amended): A mutant *ras* peptide-carrier molecule conjugate comprising the mutant *ras* peptide claim 10 or 72 and a carrier molecule, wherein said carrier molecule enhances the immunogenicity of the peptide.

Claim 26. (canceled).

Claim 27. (**currently amended** ~~previously presented~~) An immunogen for eliciting a mutant *ras* peptide-specific human CD8<sup>+</sup> cytotoxic T lymphocyte immune response comprising a mutant *ras* peptide of claim 10 or 72, wherein the immunogen elicits a mutant *ras* peptide-specific human CD8<sup>+</sup> cytotoxic T lymphocyte immune response.

Claims 28-31. (canceled).

Claim 32. (currently **amended** ~~ammended~~) A pharmaceutical composition comprising the mutant *ras* peptide of claim 10 or 72 and a pharmaceutically acceptable carrier.

Claim 33. (previously presented) The pharmaceutical composition of claim 32, further comprising a biological response modifier.

Claim 34. (previously presented) The pharmaceutical composition of claim 32, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

Claims 35-65. (canceled).

Claim 66. (previously presented) The mutant *ras* peptide-carrier molecule conjugate of claim 25, wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus toxoid-CD4 epitope, *Pseudomonas* exotoxin A, and poly-L-lysine.

Claim 67. (previously presented) The mutant *ras* peptide-carrier molecule conjugate of claim 25, wherein the carrier molecule is tetanus toxoid.

Claim 68. (previously presented) The pharmaceutical composition of claim 33, wherein the biological response modifier is interleukin 2.

Claim 69. (canceled).

Claim 70. (previously presented) The pharmaceutical composition of claim 32, further comprising interleukin 2, interleukin 6, interleukin 12, interferon, tumor necrosis factor, GM-CSF,  $\beta$ 2-microglobulin, or combinations thereof.

Claim 71. (previously presented) The pharmaceutical composition of claim 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.

Claim 72. (new) A mutant *ras* peptide comprising:  
an amino acid sequence of at least 8 amino acids, wherein said amino acid from the sequence comprises consisting of Tyr Xaa<sub>1</sub> Leu Xaa<sub>2</sub> Val Val Gly Ala Xaa<sub>3</sub> Gly Val Gly Lys Ser (SEQ ID NO:16);

wherein Xaa<sub>1</sub> is the amino acid lysine or tyrosine;

wherein Xaa<sub>2</sub> is an amino acid;

wherein Xaa<sub>3</sub> is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, or and serine;

wherein when Xaa<sub>2</sub> is valine, Xaa<sub>1</sub> is tyrosine

and said peptide elicits a peptide-specific human CD8<sup>+</sup> cytotoxic T lymphocyte immune response.

Applicants do not believe that any filing or extension fees are required. In the event that this is not correct, Applicants request an extension of time and authorize the Commissioner to charge the undersigned's Deposit Account No. 08-1641.

Respectfully submitted,

Date: June 9, 2005

Customer No. 44991  
HELLER EHRMAN LLP  
1717 Rhode Island Avenue NW  
Washington, DC 20036-3001  
Telephone: (202) 912-2000  
Facsimile: (202) 912-2020

By Patricia D. Granados

Patricia D. Granados  
Agent for Applicants  
Registration No. 33,683